TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hormones and Physical Exercise (HOPE) Study
Brief Summary: The investigators propose to examine 121 postmenopausal women diagnosed with hormone-receptor positive breast cancer who have been taking aromatase inhibitors (AI) for at least 6 months and are experiencing at least mild arthralgia originating during AI treatment, the yearlong effect of exercise vs. attention control (health education), and on toxic side effects of AI.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Attention Control (Health Education); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control (Health Education) | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Attention Control (Health Education); Assigned to Arm(s): Attention Control (Health Education)
B: Arm Label: Group I (yoga-based rehabilitation program); Type: EXPERIMENTAL; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Arm Label: Group II (standard care/control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Quality-of-Life Assessment, Procedure: Yoga | Intervention Type: PROCEDURE; Name: Quality-of-Life Assessment; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control) | Intervention Type: PROCEDURE; Name: Yoga; Assigned to Arm(s): Group I (yoga-based rehabilitation program), Group II (standard care/control)
C: Arm Label: Arm I (Control); Type: ACTIVE_COMPARATOR; Interventions: Other: questionnaire administration, Procedure: quality-of-life assessment, Procedure: management of therapy complications | Arm Label: Arm II (Exercise); Type: EXPERIMENTAL; Interventions: Other: questionnaire administration, Procedure: quality-of-life assessment, Procedure: management of therapy complications, Behavioral: exercise intervention | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): Arm II (Exercise)
D: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical exercise, Other: best supportive care | Arm Label: No exercise; Type: OTHER; Interventions: Other: best supportive care | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): Exercise | Intervention Type: OTHER; Name: best supportive care; Assigned to Arm(s): Exercise, No exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hormones and Physical Exercise (HOPE) Study
Brief Summary: The investigators propose to examine 121 postmenopausal women diagnosed with hormone-receptor positive breast cancer who have been taking aromatase inhibitors (AI) for at least 6 months and are experiencing at least mild arthralgia originating during AI treatment, the yearlong effect of exercise vs. attention control (health education), and on toxic side effects of AI.


Options:
A: Arm Label: T+OFS; Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Drug: triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: exemestane, Drug: triptorelin | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): E+OFS | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): T+OFS | Intervention Type: DRUG; Name: triptorelin; Assigned to Arm(s): E+OFS, T+OFS
B: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Attention Control (Health Education); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control (Health Education) | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Attention Control (Health Education); Assigned to Arm(s): Attention Control (Health Education)
C: Arm Label: Tamoxifen; Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Drug: Tamoxifen | Arm Label: T+OFS; Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Tamoxifen, Drug: Triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: Exemestane, Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Triptorelin | Intervention Type: DRUG; Name: Exemestane; Assigned to Arm(s): E+OFS | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: PROCEDURE; Name: Oophorectomy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: DRUG; Name: Tamoxifen; Assigned to Arm(s): T+OFS, Tamoxifen | Intervention Type: DRUG; Name: Triptorelin; Assigned to Arm(s): E+OFS, T+OFS
D: Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hormones and Physical Exercise (HOPE) Study
Brief Summary: The investigators propose to examine 121 postmenopausal women diagnosed with hormone-receptor positive breast cancer who have been taking aromatase inhibitors (AI) for at least 6 months and are experiencing at least mild arthralgia originating during AI treatment, the yearlong effect of exercise vs. attention control (health education), and on toxic side effects of AI.


Options:
A: Arm Label: aerobic resistance; Type: EXPERIMENTAL; Interventions: Behavioral: aerobic resistance exercise | Arm Label: home based physical activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: home based health promotion | Intervention Type: BEHAVIORAL; Name: aerobic resistance exercise; Assigned to Arm(s): aerobic resistance | Intervention Type: BEHAVIORAL; Name: home based health promotion; Assigned to Arm(s): home based physical activity
B: Arm Label: Lymphedema Care Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise only; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention | Arm Label: Weight loss only; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Loss Intervention | Arm Label: Exercise and Weight loss combined; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Behavioral: Weight Loss Intervention | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise and Weight loss combined, Exercise only | Intervention Type: BEHAVIORAL; Name: Weight Loss Intervention; Assigned to Arm(s): Exercise and Weight loss combined, Weight loss only
C: Arm Label: weight loss intervention; Type: EXPERIMENTAL; Interventions: Behavioral: weight loss intervention | Arm Label: Weight Loss plus Resistance Training; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Loss | Arm Label: Comparator; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight Loss | Intervention Type: BEHAVIORAL; Name: weight loss intervention; Assigned to Arm(s): weight loss intervention | Intervention Type: BEHAVIORAL; Name: Weight Loss; Assigned to Arm(s): Weight Loss plus Resistance Training | Intervention Type: BEHAVIORAL; Name: Weight Loss; Assigned to Arm(s): Comparator
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Attention Control (Health Education); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control (Health Education) | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Attention Control (Health Education); Assigned to Arm(s): Attention Control (Health Education)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Human Thalamocortical Network in Tourette Syndrome
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of deep brain stimulation (DBS) as a possible new treatment for Tourette Syndrome (TS).

This investigation will (1) test the hypothesis that centromedian (CM) continuous brain stimulation will be an effective, safe method for the treatment of tics in medication refractory TS, (2) will define the intra-operative and post-operative physiological changes, and (3) will test the hypothesis that responsive brain stimulation (RBS) will provide an alternative to chronic DBS in TS.


Options:
A: Intervention Type: DEVICE; Name: high frequency stimulation; Assigned to Arm(s): N/A
B: Arm Label: ODT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal drug therapy | Arm Label: DBS+ODT; Type: EXPERIMENTAL; Interventions: Device: B-STN DBS, Drug: Optimal drug therapy | Intervention Type: DEVICE; Name: B-STN DBS; Assigned to Arm(s): DBS+ODT | Intervention Type: DRUG; Name: Optimal drug therapy; Assigned to Arm(s): DBS+ODT, ODT
C: Arm Label: Continuous Deep Brain Stimulation (DBS); Type: EXPERIMENTAL; Interventions: Device: Continuous DBS | Arm Label: Responsive Brain Stimulation (RBS Setting); Type: EXPERIMENTAL; Interventions: Device: Responsive Brain Stimulation (RBS Setting) | Intervention Type: DEVICE; Name: Continuous DBS; Assigned to Arm(s): Continuous Deep Brain Stimulation (DBS) | Intervention Type: DEVICE; Name: Responsive Brain Stimulation (RBS Setting); Assigned to Arm(s): Responsive Brain Stimulation (RBS Setting)
D: Arm Label: DBS Off first; Type: EXPERIMENTAL; Interventions: Procedure: Bilateral GPi Deep Brain Stimulation | Arm Label: DBS On First; Type: EXPERIMENTAL; Interventions: Procedure: Bilateral GPi Deep Brain Stimulation | Intervention Type: PROCEDURE; Name: Bilateral GPi Deep Brain Stimulation; Assigned to Arm(s): DBS Off first, DBS On First

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega 3 for Comorbid Depression and Heart Failure Treatment
Brief Summary: Omega 3 supplements will improve depressive symptoms to a greater extent than placebo in heart failure patients with moderate to severe major depressive disorder.


Options:
A: Arm Label: Omega-3 supplement; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplement; Assigned to Arm(s): Omega-3 supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Corn Oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Corn oil | Arm Label: Omega-3 Fatty Acids; Type: EXPERIMENTAL; Interventions: Drug: Omega 3 Fatty Acids | Intervention Type: DRUG; Name: Omega 3 Fatty Acids; Assigned to Arm(s): Omega-3 Fatty Acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn oil; Assigned to Arm(s): Corn Oil
C: Arm Label: 2:1 EPA/DHA; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2:1 EPA/DHA | Arm Label: High EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: High EPA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: 2:1 EPA/DHA; Assigned to Arm(s): 2:1 EPA/DHA | Intervention Type: DRUG; Name: High EPA; Assigned to Arm(s): High EPA | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 Fatty Acid Supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acid Supplement; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial
Brief Summary: In countries with a high tuberculosis (TB) prevalence, TB and invasive bacterial infections are leading causes of early death in patients who initiate antiretroviral therapy (ART) with advanced immunodeficiency.

We hypothesize that a systematic 6-month empirical TB treatment initiated 2 weeks before the introduction of ART in HIV-infected adults with severe immunosuppression (CD4\<100/mm3) and no overt evidence of TB will reduce the risk of death and invasive bacterial infections. This strategy will be compared to one of extensive TB testing using point-of-care tests (Xpert MTB/RIF® and urine lipoarabinomanan LAM) and chest X-ray to identify and treat only patients with at least one positive test suggestive of TB.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Xpert MTB/RIF Ultra (Ultra) | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert MTB/RIF Ultra (Ultra); Assigned to Arm(s): Interventional
B: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
C: Arm Label: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray; Type: EXPERIMENTAL; Interventions: Device: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray, Drug: ART (Atripla, Truvada, Efavirenz, Combivir), Drug: Rifampin, isoniazid, pyrazinamide, ethambutol | Arm Label: Rifampin, isoniazid, pyrazinamide, ethambutol; Type: EXPERIMENTAL; Interventions: Drug: ART (Atripla, Truvada, Efavirenz, Combivir), Drug: Rifampin, isoniazid, pyrazinamide, ethambutol | Intervention Type: DEVICE; Name: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray; Assigned to Arm(s): Xpert MTB/RIF®, Determine TB LAM, Chest X-ray | Intervention Type: DRUG; Name: ART (Atripla, Truvada, Efavirenz, Combivir); Assigned to Arm(s): Rifampin, isoniazid, pyrazinamide, ethambutol, Xpert MTB/RIF®, Determine TB LAM, Chest X-ray | Intervention Type: DRUG; Name: Rifampin, isoniazid, pyrazinamide, ethambutol; Assigned to Arm(s): Rifampin, isoniazid, pyrazinamide, ethambutol, Xpert MTB/RIF®, Determine TB LAM, Chest X-ray
D: Arm Label: Smear; Type: ACTIVE_COMPARATOR; Interventions: Other: Smear | Arm Label: GeneXpert; Type: EXPERIMENTAL; Interventions: Other: Xpert | Intervention Type: OTHER; Name: Xpert; Assigned to Arm(s): GeneXpert | Intervention Type: OTHER; Name: Smear; Assigned to Arm(s): Smear

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Background: Increase in skin colonization of Staphylococcus aureus (S. aureus) in atopic dermatitis patients (AD) resulted from the reduction of cathelicidin production in these patients plays the important role in pathogenesis of this disease. Recently in vivo study has showed that vitamin D can stimulate cathelicidin production. Oral supplement of vitamin D might be beneficial in atopic dermatitis.

Objective: To determine the effect of oral vitamin D supplement on clinical impact including skin colonization of S. aureus in atopic dermatitis patients.


Options:
A: Arm Label: Atopic dermatitis patients: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral vitamin D | Arm Label: Atopic dermatitis patients: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: oral vitamin D; Assigned to Arm(s): Atopic dermatitis patients: Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Atopic dermatitis patients: Placebo
B: Arm Label: Usual care group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: High Dose Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): High Dose Group
C: Arm Label: Arm A; Type: N/A; Interventions: Dietary Supplement: 400 IU vitamin D3 | Arm Label: Arm B; Type: N/A; Interventions: Dietary Supplement: 2000 IU vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 400 IU vitamin D3; Assigned to Arm(s): Arm A | Intervention Type: DIETARY_SUPPLEMENT; Name: 2000 IU vitamin D3; Assigned to Arm(s): Arm B
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: daily vitamin D supplement, Other: Placebo | Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D, Dietary Supplement: daily vitamin D supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: daily vitamin D supplement; Assigned to Arm(s): Placebo, Vitamin D | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress
Brief Summary: In comparison to the general population, military personnel and veterans are at increased risk of developing both substance use disorders (SUDs) and post-traumatic stress disorder (PTSD). Despite promising developments in the past decade, the treatment of patients with SUDs and comorbid PTSD is woefully inadequate (Back, 2010; Back et al., 2014; Brady et al., 2007; McCauley et al., 2012). One of the adverse effects of abused drugs is their long-term negative impact on social behavior that is thought to involve oxytocin (OT) dysregulation (McGregor et al., 2008). In preclinical and clinical experiments, local, intra-nasal, or systemic OT administration decreases activation of the amygdala in response to visual fearful/threatening stimuli (Kirsch et al., 2005), ameliorates the effects of stressful events, and decreases drug-taking and seeking behavior (McGregor et al., 2008; Baskerville and Douglas, 2010; Carson et al., 2010a; Bowen et al., 2011; Cox et al 2013). However, little attention has been focused on whether OT decreases SUD vulnerability after exposure to traumatic stress in preclinical or clinical studies. This clinical project will determine whether intra-nasally administered OT will decrease craving (Aim 1) to use alcohol and decrease stress reactivity (Aim 2) following exposure to laboratory-induced stress (Trier Social Stress Task) among veterans with a dual diagnosis of alcohol use disorder and PTSD.


Options:
A: Arm Label: Ganaxolone; Type: EXPERIMENTAL; Interventions: Drug: Ganaxolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ganaxolone; Assigned to Arm(s): Ganaxolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Experimental ketamine group; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Active control midazolam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Experimental ketamine group | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Active control midazolam group
C: Arm Label: Propranolol; Type: EXPERIMENTAL; Interventions: Drug: Propranolol is available in generic form as the Wyeth product under the trade name Inderal. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Propranolol is available in generic form as the Wyeth product under the trade name Inderal. | Intervention Type: DRUG; Name: Propranolol is available in generic form as the Wyeth product under the trade name Inderal.; Assigned to Arm(s): Placebo, Propranolol
D: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of Mindfulness Based Compassionate Living in Recurrent Depression
Brief Summary: Since a few years, Mindfulness Based Cognitive Therapy (MBCT) has been used as treatment for patients suffering from recurrent depression. Though a number of studies show that MBCT is effective in this population and MBCT reduces the chances of relapse/recurrence in recurrent depressive patients, the chance of a new depression developing after end of treatment is still considerable. Ergo, there is room for improvement.

Especially the development of a non-judging or compassionate attitude towards all experience seems to mediate the treatment effect. It is therefore our expectation that a follow-up intervention that focuses specifically on self-compassion could prove very useful in elaborating on the effects of MBCT.

The research question of this research is therefore: what is the effect of compassion training in people suffering from recurrent depression who have already received MBCT training?


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram, Behavioral: Interpersonal Psychotherapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram, Behavioral: Clinical Monitoring | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Clinical Monitoring; Assigned to Arm(s): 2
B: Arm Label: MBCL + TAU; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Compassionate Living | Arm Label: TAU; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Compassionate Living; Assigned to Arm(s): MBCL + TAU
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency Management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Non Contingent Control Condition | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Non Contingent Control Condition; Assigned to Arm(s): 2

Answer: B